gefitinib and bms 387032
gefitinib has been researched along with bms 387032 in 7 studies
Compound Research Comparison
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (bms 387032) | Trials (bms 387032) | Recent Studies (post-2010) (bms 387032) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 76 | 3 | 56 |
Protein Interaction Comparison
Protein | Taxonomy | gefitinib (IC50) | bms 387032 (IC50) |
---|---|---|---|
Cyclin-T1 | Homo sapiens (human) | 0.0103 | |
G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.48 | |
G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.048 | |
Vitamin K-dependent protein C | Homo sapiens (human) | 0.264 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.48 | |
Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.7538 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.48 | |
Cyclin-A2 | Homo sapiens (human) | 0.0427 | |
G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.925 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.046 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0426 | |
G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.925 | |
G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.925 | |
Cannabinoid receptor 2 | Mus musculus (house mouse) | 0.062 | |
Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.0772 | |
Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.1078 | |
Cyclin-H | Homo sapiens (human) | 0.0823 | |
CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.1027 | |
Cyclin-A1 | Homo sapiens (human) | 0.021 | |
Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.34 | |
Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.34 | |
G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.48 |
Research
Studies (7)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors
Authors | Studies |
---|---|
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
Russu, WA; Shallal, HM | 1 |
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Cai, GX; Chen, GX; Chen, X; Deng, YF; Huang, HB; Kong, WY; Lei, QC; Liao, YN; Liu, Y; Shao, ZL; Sun, WS; Wang, R; Wu, SG; Yu, CF; Zhuang, XF | 1 |
Other Studies
7 other study(ies) available for gefitinib and bms 387032
Article | Year |
---|---|
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Homeodomain Proteins; Humans; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Ribosomal Proteins; Sorafenib | 2023 |